50 Medicines Substandard; Including Fever, Blood Pressure
The company claimed that this batch did not belong to them and described it as counterfeit.
Representation of medicines.
In a recent survey conducted by the Central Drug Standards Control Organisation (CDSCO), more than 50 drugs prescribed frequently for various conditions have been found to be of inferior quality.
As per a report by TOI, these drugs are being sold in the market despite not meeting the required safety and efficacy standards.
Some of the drugs include fever, acid reflux, blood pressure, diabetes, and acid reflux.
According to data from the previous month, multiple batches of medications produced by well-known pharmaceutical companies did not meet the quality standards set by CDSCO.
A recent case involved a batch of Pulmosil (Sildenafil injection) produced by Sun Pharmaceuticals that was found to be of low quality.
The company claimed that this batch did not belong to them and described it as counterfeit
Similarly, another batch of Pantocid, a common treatment for acid reflux, was also reported as counterfeit.
Glenmark Pharmaceuticals, another major player in the industry, came under scrutiny for a batch of Telma H (Telmisartan 40mg and Hydrochlorothiazide 12.5mg tablets IP), used for managing high blood pressure.
Glenmark denied any involvement with the flagged batch.
A batch of Clavam 625, which includes Amoxicillin and Potassium Clavulanate tablets from Alkem Health Science, was found to not meet quality standards.
Addressing concerns about drug safety, a senior official from CDSCO clarified that the failure of one batch to comply with regulations does not mean that all products under that brand are of poor quality.
Quality issues are monitored regularly and are addressed quickly to avert any potential public health risks.
CDSCO, as the regulatory authority in charge of drug approvals and clinical trials, carries out routine random sampling of medications to ensure compliance with Good Manufacturing Practices (GMP).
While there has not been a notable increase in cases of substandard drugs, officials highlighted the government's ongoing commitment to enhancing manufacturing processes and ensuring compliance with quality standards.
